ORIGINAL RESEARCH article
Front. Nutr.
Sec. Clinical Nutrition
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1615671
This article is part of the Research TopicFODMAPs: Advances in Research and Clinical PracticeView all 3 articles
Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients
Provisionally accepted
Umael Khan1*
Ingeborg Brønstad1
Eline Margrete Randulff Hillestad1,2Elisabeth Kjelsvik Steinsvik1
Trygve Hausken1,2Birgitte Berentsen1,2Gülen Arslan Lied1,2*- 1Haukeland University Hospital, Bergen, Norway
- 2University of Bergen, Bergen, Hordaland, Norway
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) as well as glucagon-like peptide-1 (GLP-1) have independently been implicated in irritable bowel syndrome (IBS) pathophysiology. However, there is a lack of studies that assess how low FODMAP diet affects circulating GLP-1 levels in IBS patients.Methods: Thirty patients with either diarrhea or mixed type IBS were recruited and undertook low FODMAP diet for 12 weeks. Plasma GLP-1 levels, IBS Severity Scoring System (IBS-SSS), body weight and FODMAP intake were assessed before and after the 12-week dietary intervention.Key results: Following a low FODMAP diet, average IBS-SSS and body weight were reduced (p <0.01) and plasma GLP-1 level was increased (p=0.027).Our study indicates that a 12-week low FODMAP diet may increase plasma glucagon-like peptide-1 levels in IBS patients. The underlying mechanism for this increase remains to be understood.
Keywords: FODMAP, IBS, GLP-1, Incretins, Gut Microbiota, brain-gut
Received: 21 Apr 2025; Accepted: 29 Jul 2025.
Copyright: © 2025 Khan, Brønstad, Hillestad, Steinsvik, Hausken, Berentsen and Lied. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Umael Khan, Haukeland University Hospital, Bergen, Norway
Gülen Arslan Lied, University of Bergen, Bergen, 5020, Hordaland, Norway
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.